In contrast, 2-DG seems to decrease the efficacy of anti-EGFR therapy by erlotinib application in a xenograft model of HNSCC tumors, possibly via induction of cytoprotective autophagy [27]. Here, EGFR is linked to head and neck squamous cell carcinoma.